Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TransCon IL-2 beta/gamma by Ascendis Pharma for Small-Cell Lung Cancer: Likelihood of Approval
TransCon IL-2 beta/gamma is under clinical development by Ascendis Pharma and currently in Phase II for Small-Cell Lung Cancer. According...
TransCon IL-2 beta/gamma by Ascendis Pharma for Human Papillomavirus (HPV) Associated Cancer: Likelihood of Approval
TransCon IL-2 beta/gamma is under clinical development by Ascendis Pharma and currently in Phase II for Human Papillomavirus (HPV) Associated...
Risk adjusted net present value: What is the current valuation of Ascendis Pharma's TransCon IL-2 beta/gamma?
TransCon IL-2 beta/gamma is a recombinant protein commercialized by Ascendis Pharma, with a leading Phase II program in Cervical Cancer....